Bayer Schering Expects Thailand To Be Leading Medical Hub
This article was originally published in PharmAsia News
Bayer Schering Pharma Thailand expects the country to become a leading medical hub and its health care market to grow beyond its current $2.7 billion estimated value. Uwe Dalichow, country division head of the firm, said it expects its Thai business to grow with the market or even exceed the market average. He said he did not expect the pharmaceutical market in Thailand to be affected by challenges facing the rest of the industry and expected the market to grow by 13.1 percent 2012. (Click here for more
You may also be interested in...
A WHO recommendation to explicitly exempt low-THC CBD from international narcotics controls has been emphatically rejected by UN member states. The CBD industry had hoped for a positive outcome to remove regulatory pressure on product manufacturers in Europe and around the world.
After its historic first emergency approval, analysts at Bernstein has upgraded predictions for Pfizer/BioNTech's COVID-19 vaccine in 2021 and beyond.
How UK and EU device regulations will differ in 2021, UK approved bodies and Northern Ireland's unfettered access to the UK market were key themes at the ABHI’s annual regulatory conference.